Alarm was felt across the biopharma world after Amgen Inc.’s Oct. 27 commentary about the impact of competition and pricing pressures on the anti-tumor necrosis factor market, but AbbVie Inc. – with a business model built around its TNF inhibitor Humira – sought to paint a different picture Oct. 28, saying indications are good across several metrics for continued strong performance by its top-seller.
In what many analysts called a weak quarterly performance, AbbVie reported worldwide net revenues of $6.43bn for the third quarter,...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?